The DOI matches its Crossref record; 248 of the 248 references it cites were found in a registry or an index.
Prognostic and predictive biomarkers in breast cancer: Past, present and future
Abstract
Following a diagnosis of breast cancer, the most immediate challenges in patient management are the determination of prognosis and identification of the most appropriate adjuvant systemic therapy. Determining prognosis can best be addressed with a combination of traditional clinicopathological prognostic factors, biomarkers such as HER2/neu and specific multigene genes tests. Amongst the best validated prognostic multigene tests are uPA/PAI1, Oncotype DX and MammaPrint. Oncotype DX and MammaPrint, may be used for predicting outcome and aiding adjunct therapy decision making in patients with ER-positive, HER2-negative breast cancers that are either lymph node-negative or node positive (1-3 metastatic nodes), while uPA/PAI-1 may be similarly used in ER-positive, lymph node-negative patients. For selecting likely response to endocrine therapy, both estrogen receptors (ER) and progesterone receptors (PR) should be measured. On the other hand, for identifying likely response to anti-HER2 therapy, determination of HER2 gene amplification or overexpression is necessary. To identify new prognostic and predictive biomarkers for breast cancer, current research is focusing on tumor and circulating DNA (ctDNA) and RNA (e.g., micro RNAs) and circulating tumor cells. A promising ctDNA biomarker is the mutational status of ER (ESR1) for predicting the emergence of resistance to aromatase inhibitors. Challenges for future research include the identification of biomarkers for predicting response to radiotherapy and specific forms of chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: MicroRNA-138 modulates metastasis and EMT in breast cancer cells by targeting vimentin
Zhang, J., Liu, D., Feng, Z., Mao, J., Zhang, C., Lü, Y., Li, J., Zhang, Q., Li, Q., & Li, L. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.12.018 · Cited by 98
RetractedA Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,593
Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., Vadas, M. A., Khew-Goodall, Y., & Goodall, G. J. (2008) · Nature Cell Biology · doi:10.1038/ncb1722 · Cited by 3,863
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Tumour invasion and metastasis initiated by microRNA-10b in breast cancer
Ma, L., Teruya-Feldstein, J., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06174 · Cited by 2,605
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F. L., Watson, D., Bryant, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7985 · Cited by 2,579
Gianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.-A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,374
Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases
Carter, C. L., Allen, C., & Henson, D. E. (1989) · Cancer · doi:10.1002/1097-0142(19890101)63:1<181::aid-cncr2820630129>3.0.co;2-h · Cited by 2,288
Drug delivery with carbon nanotubes for in vivo cancer treatment
Liu, Z., Chen, K., Davis, C. R., Sherlock, S. P., Cao, Q., Chen, X. S., & Dai, H. (2008) · PubMed · doi:10.48550/arxiv.0808.2070 · Cited by 2,286
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220
Jahr, S., Hentze, H., Englisch, S., Hardt, D., Fackelmayer, F. O., Hesch, R. D., & Knippers, R. (2001) · PubMed · Cited by 2,169
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
Cardoso, F., van’t Veer, L. J., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., Pierga, J.-Y., Brain, E., Causeret, S., DeLorenzi, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602253 · Cited by 1,994
Fraga, M. F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C., Ropero, S., Petrie, K., et al. (2005) · Nature Genetics · doi:10.1038/ng1531 · Cited by 1,923
Endogenous human microRNAs that suppress breast cancer metastasis
Tavazoie, S. F., Alarcón, C., Oskarsson, T., Padua, D., Wang, Q., Bos, P. D., Gerald, W. L., & Massagué, J. (2008) · Nature · doi:10.1038/nature06487 · Cited by 1,857
Vogelstein, B., & Kinzler, K. W. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9236 · Cited by 1,770
Loi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Van Eenoo, F., Rouas, G., Francis, P., Crown, J. P. A., Hitre, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0902 · Cited by 1,632
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rutgers, E., Zackrisson, S., & Cardoso, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv298 · Cited by 1,597
Gnirke, A., Melnikov, A., Maguire, J., Rogov, P., LeProust, E. M., Brockman, W., Fennell, T., Giannoukos, G., Fisher, S., Russ, C., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1523 · Cited by 1,433
Albain, K. S., Barlow, W. E., Shak, S., Hortobagyi, G. N., Livingston, R. B., Yeh, I.-T., Ravdin, P., Bugarini, R., Baehner, F. L., Davidson, N. E., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70314-6 · Cited by 1,407
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Perez, E. A., Olson, J. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510764 · Cited by 1,388
MicroRNA-10a binds the 5’UTR of ribosomal protein mRNAs and enhances their translation
Ørom, U. A., Nielsen, F. C., & Lund, A. H. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.05.001 · Cited by 1,384
A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer
Braun, S., Vogl, F. D., Naume, B., Janni, W., Osborne, M. P., Coombes, R. C., Schlimok, G., Diel, I. J., Gerber, B., Gebauer, G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050434 · Cited by 1,379
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis
Ma, L., Young, J., Prabhala, H., Pan, E., Mestdagh, P., Muth, D., Teruya-Feldstein, J., Reinhardt, F., Onder, T. T., Valastyan, S., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2024 · Cited by 1,336
Histones and histone modifications
Peterson, C. L., & Laniel, M.-A. (2004) · Current Biology · doi:10.1016/j.cub.2004.07.007 · Cited by 1,313
Forshew, T., Murtaza, M., Parkinson, C., Gale, D., Tsui, D. W. Y., Kaper, F., Dawson, S.-J., Piskorz, A. M., Jimenez-Linan, M., Bentley, D., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003726 · Cited by 1,297
Loi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., Fumagalli, D., Kellokumpu-Lehtinen, P.-L., Bono, P., Kataja, V., Desmedt, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu112 · Cited by 1,256
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Buyse, M., Loi, S., van't Veer, L., Viale, G., Delorenzi, M., Glas, A. M., Saghatchian d'Assignies, M., Bergh, J., Lidereau, R., Ellis, P., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj329 · Cited by 1,238
Yan, L.-X., Huang, X.-F., Shao, Q., Huang, M.-Y., Deng, L., Wu, Q.-L., Zeng, Y.-X., & Shao, J.-Y. (2008) · RNA · doi:10.1261/rna.1034808 · Cited by 1,148
Loibl, S., & Gianni, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32417-5 · Cited by 1,116
Cameron, D., Piccart-Gebhart, M. J., Gelber, R. D., Procter, M., Goldhirsch, A., de Azambuja, E., Castro, G., Untch, M., Smith, I., Gianni, L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32616-2 · Cited by 1,035
Hayes, D. F., Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Miller, M. C., Matera, J., Allard, W. J., Doyle, G. V., & Terstappen, L. W. W. M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2821 · Cited by 1,030
The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis
Huang, Q., Gumireddy, K., Schrier, M., le Sage, C., Nagel, R., Nair, S., Egan, D. A., Li, A., Huang, G., Klein-Szanto, A. J., et al. (2008) · Nature Cell Biology · doi:10.1038/ncb1681 · Cited by 975
Giuliano, A. E., Connolly, J. L., Edge, S. B., Mittendorf, E. A., Rugo, H. S., Solin, L. J., Weaver, D. L., Winchester, D. J., & Hortobagyi, G. N. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21393 · Cited by 961
Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility
Yu, M., Bardia, A., Aceto, N., Bersani, F., Madden, M. W., Donaldson, M. C., Desai, R., Zhu, H., Comaills, V., Zheng, Z., et al. (2014) · Science · doi:10.1126/science.1253533 · Cited by 913
Dressman, D., Yan, H., Traverso, G., Kinzler, K. W., & Vogelstein, B. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1133470100 · Cited by 844
Bidard, F.-C., Peeters, D. J., Fehm, T., Nolé, F., Gisbert-Criado, R., Mavroudis, D., Grisanti, S., Generali, D., Garcia-Saenz, J. A., Stebbing, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70069-5 · Cited by 838
Bertoli, G., Cava, C., & Castiglioni, I. (2015) · Theranostics · doi:10.7150/thno.11543 · Cited by 815
Harris, L. N., Ismaila, N., McShane, L. M., Andre, F., Collyar, D. E., Gonzalez-Angulo, A. M., Hammond, E. H., Kuderer, N. M., Liu, M. C., Mennel, R. G., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.2289 · Cited by 811
Bardou, V.-J., Arpino, G., Elledge, R. M., Osborne, C. K., & Clark, G. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.099 · Cited by 752
MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1
Miller, T. E., Ghoshal, K., Ramaswamy, B., Roy, S., Datta, J., Shapiro, C. L., Jacob, S., & Majumder, S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804612200 · Cited by 749
Cuzick, J., Dowsett, M., Pineda, S., Wale, C., Salter, J., Quinn, E., Zabaglo, L., Mallon, E., Green, A. R., Ellis, I. O., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.2835 · Cited by 739
EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition
中川, 学. (2014) · Institutional Repositories DataBase (IRDB) · Cited by 736
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
Fribbens, C., O’Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., Cristofanilli, M., Andre, F., Loi, S., Loibl, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3061 · Cited by 722
ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
Jeselsohn, R., Buchwalter, G., De Angelis, C., Brown, M., & Schiff, R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.117 · Cited by 704
hsa-miR-210 Is Induced by Hypoxia and Is an Independent Prognostic Factor in Breast Cancer
Camps, C., Buffa, F. M., Colella, S., Moore, J., Sotiriou, C., Sheldon, H., Harris, A. L., Gleadle, J. M., & Ragoussis, J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1755 · Cited by 662
Progesterone receptor modulates ERα action in breast cancer
Mohammed, H., Russell, I. A., Stark, R., Rueda, O. M., Hickey, T. E., Tarulli, G. A., Serandour, A. A., Birrell, S. N., Bruna, A., Saadi, A., et al. (2015) · Nature · doi:10.1038/nature14583 · Cited by 659
Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500
Smerage, J. B., Barlow, W. E., Hortobagyi, G. N., Winer, E. P., Leyland-Jones, B., Srkalovic, G., Tejwani, S., Schott, A. F., O'Rourke, M. A., Lew, D. L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2561 · Cited by 648
Prognostic and Predictive Factors in Early-Stage Breast Cancer
Cianfrocca, M., & Goldstein, L. J. (2004) · The Oncologist · doi:10.1634/theoncologist.9-6-606 · Cited by 637
Kovalchuk, O., Filkowski, J., Meservy, J., Ilnytskyy, Y., Tryndyak, V. P., Chekhun, V. F., & Pogribny, I. P. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0021 · Cited by 635
Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients
Rack, B., Schindlbeck, C., Jückstock, J., Andergassen, U., Hepp, P., Zwingers, T., Friedl, T. W. P., Lorenz, R., Tesch, H., Fasching, P. A., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju066 · Cited by 615
Salgado, R., Denkert, C., Campbell, C., Savas, P., Nuciforo, P., Aura, C., de Azambuja, E., Eidtmann, H., Ellis, C. E., Baselga, J., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0830 · Cited by 605
Small RNA sorting: matchmaking for Argonautes
Czech, B., & Hannon, G. J. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2916 · Cited by 605
Plasma exosome microRNAs are indicative of breast cancer
Hannafon, B. N., Trigoso, Y. D., Calloway, C. L., Zhao, Y. D., Lum, D. H., Welm, A. L., Zhao, Z. J., Blick, K. E., Dooley, W. C., & Ding, W. Q. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0753-x · Cited by 603
Look, M. P., van Putten, W. L. J., Duffy, M. J., Harbeck, N., Christensen, I. J., Thomssen, C., Kates, R., Spyratos, F., Ferno, M., Eppenberger-Castori, S., et al. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.2.116 · Cited by 596
Self-citationExpression of luminal and basal cytokeratins in human breast carcinoma
Abd El‐Rehim, D. M., Pinder, S. E., Paish, C. E., Bell, J., Blamey, R., Robertson, J. F., Nicholson, R. I., & Ellis, I. O. (2004) · The Journal of Pathology · doi:10.1002/path.1559 · Cited by 594
Konecny, G., Pauletti, G., Pegram, M., Untch, M., Dandekar, S., Aguilar, Z., Wilson, C., Rong, H.-M., Bauerfeind, I., Felber, M., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.2.142 · Cited by 588
Predicting Response to Endocrine Therapy in Human Breast Cancer: A Hypothesis
Horowitz, K. B., McGuire, W. L., Pearson, O. H., & Segaloff, A. (1975) · Science · doi:10.1126/science.168640 · Cited by 569
High Fragmentation Characterizes Tumour-Derived Circulating DNA
Mouliere, F., Robert, B., Arnau Peyrotte, E., Del Rio, M., Ychou, M., Molina, F., Gongora, C., & Thierry, A. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023418 · Cited by 567
A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells
Png, K. J., Halberg, N., Yoshida, M., & Tavazoie, S. F. (2012) · Nature · doi:10.1038/nature10661 · Cited by 531
Duffy, M. J., Harbeck, N., Nap, M., Molina, R., Nicolini, A., Senkus, E., & Cardoso, F. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.017 · Cited by 522
Self-citationThe Identification and Characterization of Breast Cancer CTCs Competent for Brain Metastasis
Zhang, L., Ridgway, L. D., Wetzel, M. D., Ngo, J., Yin, W., Kumar, D., Goodman, J. C., Groves, M. D., & Marchetti, D. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005109 · Cited by 521
Circulating tumour cells in non-metastatic breast cancer: a prospective study
Lucci, A., Hall, C. S., Lodhi, A. K., Bhattacharyya, A., Anderson, A. E., Xiao, L., Bedrosian, I., Kuerer, H. M., & Krishnamurthy, S. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70209-7 · Cited by 507
Heitzer, E., Auer, M., Gasch, C., Pichler, M., Ulz, P., Hoffmann, E. M., Lax, S., Waldispuehl-Geigl, J., Mauermann, O., Lackner, C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4140 · Cited by 497
Riethdorf, S., Müller, V., Zhang, L., Rau, T., Loibl, S., Komor, M., Roller, M., Huober, J., Fehm, T., Schrader, I., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2042 · Cited by 490
Assuring the quality of next-generation sequencing in clinical laboratory practice
Gargis, A. S., Kalman, L., Berry, M. W., Bick, D. P., Dimmock, D. P., Hambuch, T., Lu, F., Lyon, E., Voelkerding, K. V., Zehnbauer, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2403 · Cited by 461
Olsson, E., Winter, C., George, A., Chen, Y., Howlin, J., Tang, M. E., Dahlgren, M., Schulz, R., Grabau, D., van Westen, D., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404913 · Cited by 453
Janicke, F., Prechtl, A., Thomssen, C., Harbeck, N., Meisner, C., Untch, M., Sweep, C. G. J. F., Selbmann, H.-K., Graeff, H., & Schmitt, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.12.913 · Cited by 434
A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial–mesenchymal transition
Kim, N. H., Kim, H. S., Li, X.-Y., Lee, I., Choi, H.-S., Kang, S. E., Cha, S. Y., Ryu, J. K., Yoon, D., Fearon, E. R., et al. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201103097 · Cited by 432
Zhou, M., Liu, Z., Zhao, Y., Ding, Y., Liu, H., Xi, Y., Xiong, W., Li, G., Lu, J., Fodstad, O., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.083337 · Cited by 424
Kong, W., He, L., Richards, E. J., Challa, S., Xu, C.-X., Permuth-Wey, J., Lancaster, J. M., Coppola, D., Sellers, T. A., Djeu, J. Y., et al. (2014) · Oncogene · doi:10.1038/onc.2012.636 · Cited by 417
Histological grading of breast carcinomas: A study of interobserver agreement
Robbins, P., Pinder, S., de Klerk, N., Dawkins, H., Harvey, J., Sterrett, G., Ellis, I., & Elston, C. (1995) · Human Pathology · doi:10.1016/0046-8177(95)90010-1 · Cited by 416
Van Poznak, C., Somerfield, M. R., Bast, R. C., Cristofanilli, M., Goetz, M. P., Gonzalez-Angulo, A. M., Hicks, D. G., Hill, E. G., Liu, M. C., Lucas, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.1459 · Cited by 404
miR‐29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis
Gebeshuber, C. A., Zatloukal, K., & Martinez, J. (2009) · EMBO reports · doi:10.1038/embor.2009.9 · Cited by 391
Clinical utility of cytokeratins as tumor markers
Barak, V., Goike, H., Panaretakis, K. W., & Einarsson, R. (2004) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2004.05.009 · Cited by 382
Chou, J., Lin, J. H., Brenot, A., Kim, J.-W., Provot, S., & Werb, Z. (2013) · Nature Cell Biology · doi:10.1038/ncb2672 · Cited by 373
Foekens, J. A., Sieuwerts, A. M., Smid, M., Look, M. P., de Weerd, V., Boersma, A. W. M., Klijn, J. G. M., Wiemer, E. A. C., & Martens, J. W. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803304105 · Cited by 370
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists
Toy, W., Weir, H., Razavi, P., Lawson, M., Goeppert, A. U., Mazzola, A. M., Smith, A., Wilson, J., Morrow, C., Wong, W. L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1523 · Cited by 368
Baselga, J., Cortés, J., Im, S.-A., Clark, E., Ross, G., Kiermaier, A., & Swain, S. M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.5384 · Cited by 364
MicroRNAs and gene regulatory networks: managing the impact of noise in biological systems
Herranz, H., & Cohen, S. M. (2010) · Genes & Development · doi:10.1101/gad.1937010 · Cited by 364
Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer
Janni, W. J., Rack, B., Terstappen, L. W. M. M., Pierga, J.-Y., Taran, F.-A., Fehm, T., Hall, C., de Groot, M. R., Bidard, F.-C., Friedl, T. W. P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1603 · Cited by 363
Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA
Volinia, S., Galasso, M., Sana, M. E., Wise, T. F., Palatini, J., Huebner, K., & Croce, C. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200010109 · Cited by 359
Ignatiadis, M., Lee, M., & Jeffrey, S. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1190 · Cited by 355
Fehm, T., Müller, V., Aktas, B., Janni, W., Schneeweiss, A., Stickeler, E., Lattrich, C., Löhberg, C. R., Solomayer, E., Rack, B., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1163-x · Cited by 353
Zhang, Y., Yang, P., Sun, T., Li, D., Xu, X., Rui, Y., Li, C., Chong, M., Ibrahim, T., Mercatali, L., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2690 · Cited by 350
MicroRNA Sequence and Expression Analysis in Breast Tumors by Deep Sequencing
Farazi, T. A., Horlings, H. M., ten Hoeve, J. J., Mihailovic, A., Halfwerk, H., Morozov, P., Brown, M., Hafner, M., Reyal, F., van Kouwenhove, M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0608 · Cited by 346
Llombart-Cussac, A., Cortés, J., Paré, L., Galván, P., Bermejo, B., Martínez, N., Vidal, M., Pernas, S., López, R., Muñoz, M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30021-9 · Cited by 344
Rao, X., Di Leva, G., Li, M., Fang, F., Devlin, C., Hartman-Frey, C., Burow, M. E., Ivan, M., Croce, C. M., & Nephew, K. P. (2011) · Oncogene · doi:10.1038/onc.2010.487 · Cited by 342
De Laurentiis, M., Arpino, G., Massarelli, E., Ruggiero, A., Carlomagno, C., Ciardiello, F., Tortora, G., D'Agostino, D., Caputo, F., Cancello, G., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2569 · Cited by 340
Gluz, O., Nitz, U. A., Christgen, M., Kates, R. E., Shak, S., Clemens, M., Kraemer, S., Aktas, B., Kuemmel, S., Reimer, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5383 · Cited by 333
Liang, Z., Wu, H., Xia, J., Li, Y., Zhang, Y., Huang, K., Wagar, N., Yoon, Y., Cho, H. T., Scala, S., et al. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.10.017 · Cited by 330
Up-regulation of miR-21 Mediates Resistance to Trastuzumab Therapy for Breast Cancer
Gong, C., Yao, Y., Wang, Y., Liu, B., Wu, W., Chen, J., Su, F., Yao, H., & Song, E. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.216887 · Cited by 311
On behalf of the TRANSBIG consortium, Mook, S., Schmidt, M. K., Viale, G., Pruneri, G., Eekhout, I., Floore, A., Glas, A. M., Bogaerts, J., Cardoso, F., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0130-2 · Cited by 299
van Schooneveld, E., Wildiers, H., Vergote, I., Vermeulen, P. B., Dirix, L. Y., & Van Laere, S. J. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0526-y · Cited by 296
Jung, E., Santarpia, L., Kim, J., Esteva, F. J., Moretti, E., Buzdar, A. U., Di Leo, A., Le, X., Bast, R. C., Park, S., et al. (2012) · Cancer · doi:10.1002/cncr.26565 · Cited by 292
Petrelli, F., Viale, G., Cabiddu, M., & Barni, S. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3559-0 · Cited by 286
Ward, A., Balwierz, A., Zhang, J. D., Küblbeck, M., Pawitan, Y., Hielscher, T., Wiemann, S., & Sahin, Ö. (2013) · Oncogene · doi:10.1038/onc.2012.128 · Cited by 280
Luen, S. J., Salgado, R., Fox, S., Savas, P., Eng-Wong, J., Clark, E., Kiermaier, A., Swain, S. M., Baselga, J., Michiels, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30631-3 · Cited by 278
Circulating MiR-125b as a Marker Predicting Chemoresistance in Breast Cancer
Wang, H., Tan, G., Dong, L., Cheng, L., Li, K., Wang, Z., & Luo, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034210 · Cited by 275
Bueno-de-Mesquita, J. M., van Harten, W. H., Retel, V. P., van 't Veer, L. J., van Dam, F. S., Karsenberg, K., Douma, K. F., van Tinteren, H., Peterse, J. L., Wesseling, J., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70346-7 · Cited by 274
Duffy, M. J., McGowan, P. M., Harbeck, N., Thomssen, C., & Schmitt, M. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0428-4 · Cited by 273
Self-citationTargeting HER2 for the Treatment of Breast Cancer
Rimawi, M. F., Schiff, R., & Osborne, C. K. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-042513-015127 · Cited by 268
The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer
Knauer, M., Mook, S., Rutgers, E. J. T., Bender, R. A., Hauptmann, M., van de Vijver, M. J., Koornstra, R. H. T., Bueno-de-Mesquita, J. M., Linn, S. C., & van ’t Veer, L. J. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0814-2 · Cited by 267
MicroRNA-301 Mediates Proliferation and Invasion in Human Breast Cancer
Shi, W., Gerster, K., Alajez, N. M., Tsang, J., Waldron, L., Pintilie, M., Hui, A. B., Sykes, J., P'ng, C., Miller, N., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3369 · Cited by 266
Molecular profiling of single circulating tumor cells with diagnostic intention
Polzer, B., Medoro, G., Pasch, S., Fontana, F., Zorzino, L., Pestka, A., Andergassen, U., Meier‐Stiegen, F., Czyz, Z. T., Alberter, B., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201404033 · Cited by 254
Madhavan, D., Zucknick, M., Wallwiener, M., Cuk, K., Modugno, C., Scharpff, M., Schott, S., Heil, J., Turchinovich, A., Yang, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1407 · Cited by 249
miR-24 Regulates Apoptosis by Targeting the Open Reading Frame (ORF) Region of FAF1 in Cancer Cells
Qin, W., Shi, Y., Zhao, B., Yao, C., Jin, L., Ma, J., & Jin, Y. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009429 · Cited by 247
Wu, X., Somlo, G., Yu, Y., Palomares, M. R., Li, A. X., Zhou, W., Chow, A., Yen, Y., Rossi, J. J., Gao, H., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-42 · Cited by 247
Song, B., Wang, C., Liu, J., Wang, X., Lv, L., Wei, L., Xie, L., Zheng, Y., & Song, X. (2010) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-29-29 · Cited by 246
Widespread Estrogen-Dependent Repression of microRNAs Involved in Breast Tumor Cell Growth
Maillot, G., Lacroix-Triki, M., Pierredon, S., Gratadou, L., Schmidt, S., Bénès, V., Roché, H., Dalenc, F., Auboeuf, D., Millevoi, S., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2206 · Cited by 244
Yu, Z., Willmarth, N. E., Zhou, J., Katiyar, S., Wang, M., Liu, Y., McCue, P. A., Quong, A. A., Lisanti, M. P., & Pestell, R. G. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002080107 · Cited by 241
Serum MicroRNA-155 as a Potential Biomarker to Track Disease in Breast Cancer
Sun, Y., Wang, M., Lin, G., Sun, S., Li, X., Qi, J., & Li, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047003 · Cited by 239
Fehm, T., Hoffmann, O., Aktas, B., Becker, S., Solomayer, E. F., Wallwiener, D., Kimmig, R., & Kasimir-Bauer, S. (2009) · Breast Cancer Research · doi:10.1186/bcr2349 · Cited by 238
MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11
Bockhorn, J., Dalton, R., Nwachukwu, C., Huang, S., Prat, A., Yee, K., Chang, Y.-F., Huo, D., Wen, Y., Swanson, K. E., et al. (2013) · Nature Communications · doi:10.1038/ncomms2393 · Cited by 237
Ignatiadis, M., Xenidis, N., Perraki, M., Apostolaki, S., Politaki, E., Kafousi, M., Stathopoulos, E. N., Stathopoulou, A., Lianidou, E., Chlouverakis, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.7762 · Cited by 237
Kataoka, Y., Mukohara, T., Shimada, H., Saijo, N., Hirai, M., & Minami, H. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp304 · Cited by 231
Tumor-related prognostic factors for breast cancer
Donegan, W. L. (1997) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.47.1.28 · Cited by 228
Kleivi Sahlberg, K., Bottai, G., Naume, B., Burwinkel, B., Calin, G. A., Børresen-Dale, A.-L., & Santarpia, L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2011 · Cited by 228
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study
Drukker, C. A., Bueno‐de‐Mesquita, J. M., Retèl, V. P., van Harten, W. H., van Tinteren, H., Wesseling, J., Roumen, R. M. H., Knauer, M., van 't Veer, L. J., Sonke, G. S., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28082 · Cited by 227
Loibl, S., Majewski, I., Guarneri, V., Nekljudova, V., Holmes, E., Bria, E., Denkert, C., Schem, C., Sotiriou, C., Loi, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw197 · Cited by 227
Pierga, J.-Y., Bonneton, C., Vincent-Salomon, A., de Cremoux, P., Nos, C., Blin, N., Pouillart, P., Thiery, J.-P., & Magdelénat, H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0102-03 · Cited by 223
Zhu, Y., Yu, F., Jiao, Y., Feng, J., Tang, W., Yao, H., Gong, C., Chen, J., Su, F., Zhang, Y., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0071 · Cited by 221
Rothé, F., Ignatiadis, M., Chaboteaux, C., Haibe-Kains, B., Kheddoumi, N., Majjaj, S., Badran, B., Fayyad-Kazan, H., Desmedt, C., Harris, A. L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020980 · Cited by 217
Ki67 assessment in breast cancer: an update
Penault-Llorca, F., & Radosevic-Robin, N. (2017) · Pathology · doi:10.1016/j.pathol.2016.11.006 · Cited by 216
Serum CEA and CA 15-3 as prognostic factors in primary breast cancer
Ebeling, F. G., Stieber, P., Untch, M., Nagel, D., Konecny, G. E., Schmitt, U. M., Fateh-Moghadam, A., & Seidel, D. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600248 · Cited by 215
Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls
Hu, Z., Dong, J., Wang, L.-E., Ma, H., Liu, J., Zhao, Y., Tang, J., Chen, X., Dai, J., Wei, Q., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs030 · Cited by 215
Histologic grading of breast carcinoma. A reproducibility study
Dalton, L. W., Page, D. L., & Dupont, W. D. (1994) · Cancer · doi:10.1002/1097-0142(19940601)73:11<2765::aid-cncr2820731119>3.0.co;2-k · Cited by 214
Song, G., Zhang, Y., & Wang, L. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.046862 · Cited by 211
Cheng, C.-W., Wang, H.-W., Chang, C.-W., Chu, H.-W., Chen, C.-Y., Yu, J.-C., Chao, J.-I., Liu, H.-F., Ding, S.-L., & Shen, C.-Y. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2034-4 · Cited by 208
Method for grading breast cancer.
Elston, E. W., & Ellis, I. O. (1993) · Journal of Clinical Pathology · doi:10.1136/jcp.46.2.189-b · Cited by 201
Ingold Heppner, B., Untch, M., Denkert, C., Pfitzner, B. M., Lederer, B., Schmitt, W., Eidtmann, H., Fasching, P. A., Tesch, H., Solbach, C., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2338 · Cited by 200
Klein, M. E., Dabbs, D. J., Shuai, Y., Brufsky, A. M., Jankowitz, R., Puhalla, S. L., & Bhargava, R. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.36 · Cited by 196
Downregulation of miR-342 is associated with tamoxifen resistant breast tumors
Cittelly, D. M., Das, P. M., Spoelstra, N. S., Edgerton, S. M., Richer, J. K., Thor, A. D., & Jones, F. E. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-317 · Cited by 191
(2006) · New England Journal of Medicine · doi:10.1056/nejmc052564 · Cited by 189
Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer
Franken, B., de Groot, M. R., Mastboom, W. J., Vermes, I., van der Palen, J., Tibbe, A. G., & Terstappen, L. W. (2012) · Breast Cancer Research · doi:10.1186/bcr3333 · Cited by 189
Chen, W., Cai, F., Zhang, B., Barekati, Z., & Zhong, X. Y. (2013) · Tumor Biology · doi:10.1007/s13277-012-0570-5 · Cited by 177
High‐throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth
Leivonen, S.-K., Sahlberg, K. K., Mäkelä, R., Due, E. U., Kallioniemi, O., Børresen-Dale, A.-L., & Perälä, M. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2013.10.001 · Cited by 169
Harbeck, N., Schmitt, M., Meisner, C., Friedel, C., Untch, M., Schmidt, M., Sweep, C. G. J., Lisboa, B. W., Lux, M. P., Beck, T., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.01.007 · Cited by 169
Li, Q.-Q., Chen, Z.-Q., Cao, X.-X., Xu, J.-D., Xu, J.-W., Chen, Y.-Y., Wang, W.-J., Chen, Q., Tang, F., Liu, X.-P., et al. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2010.103 · Cited by 165
MicroRNA-21 Modulates Chemosensitivity of Breast Cancer Cells to Doxorubicin by Targeting PTEN
Wang, Z.-X., Lu, B.-B., Wang, H., Cheng, Z.-X., & Yin, Y.-M. (2011) · Archives of Medical Research · doi:10.1016/j.arcmed.2011.06.008 · Cited by 164
Abel, H. J., & Duncavage, E. J. (2013) · Cancer Genetics · doi:10.1016/j.cancergen.2013.11.002 · Cited by 162
MicroRNA-30a suppresses breast tumor growth and metastasis by targeting metadherin
Zhang, N., Wang, X., Huo, Q., Sun, M., Cai, C., Liu, Z., Hu, G., & Yang, Q. (2014) · Oncogene · doi:10.1038/onc.2013.286 · Cited by 161
Li, X.-F., Yan, P.-J., & Shao, Z.-M. (2009) · Oncogene · doi:10.1038/onc.2009.245 · Cited by 159
Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy
Khoo, B. L., Lee, S. C., Kumar, P., Tan, T. Z., Warkiani, M. E., Ow, S. G. W., Nandi, S., Lim, C. T., & Thiery, J. P. (2015) · Oncotarget · doi:10.18632/oncotarget.3903 · Cited by 158
Stendahl, M., Rydén, L., Nordenskjöld, B. A., Jönsson, P., Landberg, G., & Jirström, K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0248 · Cited by 155
Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients
Schwarzenbach, H., Milde‐Langosch, K., Steinbach, B., Müller, V., & Pantel, K. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-1988-6 · Cited by 153
Dieci, M. V., Prat, A., Tagliafico, E., Paré, L., Ficarra, G., Bisagni, G., Piacentini, F., Generali, D., Conte, P., & Guarneri, V. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw262 · Cited by 152
Montemurro, F., Cosimo, S. D., & Arpino, G. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt287 · Cited by 150
Suppression of miRNA-708 by Polycomb Group Promotes Metastases by Calcium-Induced Cell Migration
Ryu, S., McDonnell, K., Choi, H., Gao, D., Hahn, M., Joshi, N., Park, S.-M., Catena, R., Do, Y., Brazin, J. A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.019 · Cited by 149
Gasparini, P., Cascione, L., Fassan, M., Lovat, F., Güler, G., Balcı, S., Irkkan, Ç., Morris, Q., Croce, C. M., Shapiro, C. L., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1682 · Cited by 148
Down-regulation of microRNA-200c is associated with drug resistance in human breast cancer
Chen, J., Tian, W., Cai, H., He, H., & Deng, Y. (2011) · Medical Oncology · doi:10.1007/s12032-011-0117-4 · Cited by 147
Rodríguez-González, F. G., Sieuwerts, A. M., Smid, M., Look, M. P., Gelder, M. E. M., de Weerd, V., Sleijfer, S., Martens, J. W. M., & Foekens, J. A. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0940-x · Cited by 145
Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer
Luen, S. J., Savas, P. S., Fox, S. B., Salgado, R., & Loi, S. (2017) · Pathology · doi:10.1016/j.pathol.2016.10.010 · Cited by 140
Deciphering the divergent roles of progestogens in breast cancer
Carroll, J. S., Hickey, T. E., Tarulli, G. A., Williams, M. R., & Tilley, W. D. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.116 · Cited by 135
Downregulation of miR-21 Enhances Chemotherapeutic Effect of Taxol in Breast Carcinoma Cells
Mei, M., Ren, Y., Zhou, X., Yuan, X.-B., Han, L., Wang, G., Jia, Z., Pu, P., Kang, C., & Yao, Z. (2010) · Technology in Cancer Research & Treatment · doi:10.1177/153303461000900109 · Cited by 134
Bianchini, G., Pusztai, L., Pieńkowski, T., Im, Y., Bianchi, G., Tseng, L., Liu, M.-C., Lluch, A. M., Galeota, E., Magazzù, D., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv395 · Cited by 131
MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity
Xue, J., Chi, Y., Chen, Y., Huang, S., Ye, X., Niu, J., Wang, W., Pfeffer, L. M., Shao, Z.-M., Wu, Z.-H., et al. (2015) · Oncogene · doi:10.1038/onc.2015.96 · Cited by 124
Kwon, Y., García-Bassets, I., Hutt, K. R., Cheng, C. S., Jin, M., Liu, D., Benner, C. W., Wang, D., Ye, Z., Bibikova, M. V., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700715104 · Cited by 124
Ru, P., Steele, R., Hsueh, E. C., & Ray, R. B. (2011) · Genes & Cancer · doi:10.1177/1947601911425832 · Cited by 124
Bianchini, G., Kiermaier, A. C., Bianchi, G., Im, Y., Pieńkowski, T., Liu, M.-C., Tseng, L., Dowsett, M., Zabaglo, L. A., Kirk, S., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0806-9 · Cited by 124
Liu, S., Chia, S., Mehl, E., Leung, S. C. Y., Rajput, A. B., Cheang, M. C. U., & Nielsen, T. O. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0318-0 · Cited by 123
Ward, A., Shukla, K., Balwierz, A., Soons, Z. I. T. A., König, R., Şahin, Ö., & Wiemann, S. (2014) · The Journal of Pathology · doi:10.1002/path.4363 · Cited by 121
Applying the Nottingham Prognostic Index to a Swedish breast cancer population
Sundquist, M., Thorstenson, S., Brudin, L. H., & Nordenskjöld, B. A. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006052115874 · Cited by 118
Duffy, M. J., Duggan, C. R., Keane, R., Hill, A. D. K., McDermott, E. W. M., Crown, J. P., & O’Higgins, N. J. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.025288 · Cited by 116
Self-citationPogue–Geile, K. L., Song, N., Jeong, J., Gavin, P. G., Kim, S.-R., Blackmon, N. L., Finnigan, M., Rastogi, P., Fehrenbacher, L., Mamounas, E. P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2439 · Cited by 115
miR-497 induces apoptosis of breast cancer cells by targeting Bcl-w
Shen, L., Li, J., Xu, L., Ma, J., Li, H., Xiao, X., Zhao, J., & Fang, L. (2011) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2011.428 · Cited by 114
Deng, G. Y., Krishnakumar, S., Powell, A. A., Zhang, H., Mindrinos, M. N., Telli, M. L., Davis, R. W., & Jeffrey, S. S. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-456 · Cited by 111
miR‐515‐5p controls cancer cell migration through MARK4 regulation
Pardo, O. E., Castellano, L., Munro, C. E., Hu, Y., Mauri, F. A., Krell, J., Lara, R., Pinho, F. G., Choudhury, T., Frampton, A. E., et al. (2016) · EMBO Reports · doi:10.15252/embr.201540970 · Cited by 111
Fernandez, S. V., Bingham, C., Fittipaldi, P., Austin, L., Palazzo, J., Palmer, G. A., Alpaugh, K. R., & Cristofanilli, M. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0445-3 · Cited by 106
MicroRNA-34a Modulates Chemosensitivity of Breast Cancer Cells to Adriamycin by Targeting Notch1
Li, X., Ji, M., Zhong, S., Zha, Q.-B., Xu, J., Zhao, J., & Tang, J. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.09.007 · Cited by 103
HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials
Dent, S. F., Oyan, B., Hönig, A., Mano, M. S., & Howell, S. J. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.01.002 · Cited by 100
Markou, A. N., Yousef, G. M., Stathopoulos, E. N., Georgoulias, V., & Lianidou, E. S. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.210542 · Cited by 99
Daskalaki, A., Agelaki, S., Perraki, M., Apostolaki, S., Xenidis, N., Stathopoulos, E., Kontopodis, E., Hatzidaki, D., Mavroudis, D., & Georgoulias, V. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605183 · Cited by 98
MiRNA-155 mediates TAM resistance by modulating SOCS6-STAT3 signalling pathway in breast cancer.
Shen, R., Wang, Y., Wang, C., Yin, M., Liu, H., Chen, J., Han, J., & Wang, W.-B. (2015) · Europe PMC (PubMed Central) · Cited by 97
EJE PRIZE 2016: Mechanisms of oestrogen receptor (ER) gene regulation in breast cancer
Carroll, J. S. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0124 · Cited by 96
Li, S., Yang, X., Yang, J., Zhen, J., & Zhang, D. (2014) · Clinical and Experimental Medicine · doi:10.1007/s10238-014-0332-3 · Cited by 95
Rouzier, R., Pronzato, P., Chereau, E., Carlson, J. J., Hunt, B., & Valentine, W. J. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2559-1 · Cited by 95
Ye, X., Bai, W., Zhu, H., Zhang, X., Chen, Y., Wang, L., Yang, A., Zhao, J., & Jia, L. (2014) · BMB Reports · doi:10.5483/bmbrep.2014.47.5.165 · Cited by 94
Piwi-interacting RNAs and PIWI genes as novel prognostic markers for breast cancer
Krishnan, P., Ghosh, S., Graham, K., Mackey, J. R., Kovalchuk, O., & Damaraju, S. (2016) · Oncotarget · doi:10.18632/oncotarget.9272 · Cited by 94
Zhou, X., Marian, C., Makambi, K. H., Kosti, O., Kallakury, B., Loffredo, C. A., & Zheng, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039011 · Cited by 89
Bailey, S. T., Westerling, T., & Brown, M. A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1041 · Cited by 89
Radioguided breast surgery for occult lesion localization – correlation between two methods
Moreno, M., Wiltgen, J. E., Bodanese, B., Schmitt, R. L. D. S., Gutfilen, B., & da Fonseca, L. M. B. (2008) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-27-29 · Cited by 88
Hoppe, R., Achinger-Kawecka, J., Winter, S., Fritz, P., Lo, W., Schroth, W., & Brauch, H. B. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.07.145 · Cited by 85
Joosse, S. A., Müller, V., Steinbach, B., Pantel, K., & Schwarzenbach, H. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.360 · Cited by 84
Mulrane, L., Madden, S. F., Brennan, D. J., Gremel, G., McGee, S. F., McNally, S., Martin, F., Crown, J. P., Jirström, K., Higgins, D. G., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1420 · Cited by 84
Prognostic Implications of MicroRNA-21 Overexpression in Invasive Ductal Carcinomas of the Breast
Lee, J. A., Lee, H. Y., Lee, E. S., Kim, I., & Bae, J. W. (2011) · Journal of Breast Cancer · doi:10.4048/jbc.2011.14.4.269 · Cited by 84
Shibahara, Y., Miki, Y., Onodera, Y., Hata, S., Chan, M. S. M., Yiu, C. C. P., Loo, T. Y., Nakamura, Y., Akahira, J., Ishida, T., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4019 · Cited by 83
Krishnan, P., Ghosh, S., Wang, B., Li, D., Narasimhan, A., Berendt, R. C., Graham, K., Mackey, J. R., Kovalchuk, O., & Damaraju, S. (2015) · BMC Genomics · doi:10.1186/s12864-015-1899-0 · Cited by 83
Climent, J., Dimitrow, P., Fridlyand, J., Palacios, J., Siebert, R., Albertson, D. G., Gray, J. W., Pinkel, D., Lluch, A. M., & Martinez-Climent, J. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3307 · Cited by 82
High cell-surface density of HER2 deforms cell membranes
Chung, I., Reichelt, M., Shao, L., Akita, R. W., Koeppen, H., Rangell, L. K., Schaefer, G., Mellman, I., & Sliwkowski, M. X. (2016) · Nature Communications · doi:10.1038/ncomms12742 · Cited by 82
Zhang, B., Zhao, R., He, Y., Fu, X., Fu, L., Zhu, Z., Fu, L., & Dong, J. (2015) · Oncotarget · doi:10.18632/oncotarget.6790 · Cited by 78
Shi, W., Jiang, T., Nuciforo, P. G., Hatzis, C., Holmes, E. M., Harbeck, N., Sotiriou, C., Peña, L., Loi, S., Rosa, D. D., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw434 · Cited by 77
Wang, J., Zhao, J., Shi, M., Ding, Y., Sun, H., Yuan, F., & Zou, Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089223 · Cited by 74
Validated biomarkers: The key to precision treatment in patients with breast cancer
Duffy, M. J., O’Donovan, N., McDermott, E. W. M., & Crown, J. P. (2016) · The Breast · doi:10.1016/j.breast.2016.07.009 · Cited by 73
Self-citationZhao, R., Wu, J., Jia, W., Gong, C., Yu, F., Ren, Z., Chen, K., He, J., & Su, F. (2011) · Onkologie · doi:10.1159/000334552 · Cited by 71
Cited by
Predicting cancer outcomes with radiomics and artificial intelligence in radiology
Bera, K., Braman, N., Gupta, A., Velcheti, V., & Madabhushi, A. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00560-7 · Cited by 819
Mahmood, N., Mihalcioiu, C., & Rabbani, S. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00024 · Cited by 478
Artificial intelligence (AI) and big data in cancer and precision oncology
Dlamini, Z., Francies, F. Z., Hull, R., & Marima, R. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.08.019 · Cited by 398
Artificial intelligence in oncology
Shimizu, H., & Nakayama, K. I. (2020) · Cancer Science · doi:10.1111/cas.14377 · Cited by 388
Metadata
- Authors
- Nicolini, A., Ferrari, P., & Duffy, M. J.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 52
- Issue
- Pt 1
- Pages
- 56-73
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2752658156
- Cited by
- 424
- References
- 248
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.